Navigation Links
Nuvelo Initiates Phase 1B Clinical Trial of Anticoagulant NU172
Date:6/4/2008

at our website at http://www.nuvelo.com or by phoning 650-517-8000.

This press release contains "forward-looking statements," which include statements regarding the timing, progress and anticipated completion of Nuvelo's clinical stage and research programs, the anticipated availability of top-line data, projected operating expenses and cash usage and the potential benefits that patients may experience from the use of our clinical stage compounds, which statements are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on our management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, uncertainties relating to drug discovery and the regulatory approval process; clinical development processes; enrollment rates for patients in our clinical trials; changes in relationships with strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements; and the impact of competitive products and technological changes. These and other factors are identified and described in more detail in Nuvelo's filings with the SEC, including without limitation Nuvelo's quarterly report on Form 10-Q for the quarter ended March 31, 2008 and subsequent filings. We disclaim any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172
2. Nuvelo Announces Preclinical Data for NU206 Demonstrating Potent Therapeutic Activity in Oral Mucositis Models
3. Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
4. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
5. Nuvelo Begins Phase 2 Trial and Receives Fast Track Status for Alfimeprase in Patients With Acute Ischemic Stroke
6. Nuvelo Announces Alfimeprase SONOMA-2 Catheter Occlusion Data Presentation Webcast and Conference Call
7. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
8. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
9. Wyeth Initiates INTORACT -- A New Clinical Trial to Examine TORISEL Plus Avastin for First-Line Treatment of Advanced Kidney Cancer
10. Human Genome Sciences Initiates First Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Solid Tumors
11. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Sept. 2, 2014 Depomed, Inc. (Nasdaq: ... offer, subject to market and other conditions, $230 million ... (the "Notes"). Depomed, Inc. ("Depomed") expects to grant the ... up to an additional $34.5 million aggregate principal amount ... RBC Capital Markets, LLC will act as joint book-running ...
(Date:9/2/2014)... signs monitoring devices market with over 40% market share, ... American and European vital signs monitors markets is expected ... the end of 2013. They have been driving the ... people across these economies. The European market is expected ... rising demand for home health patient monitoring devices due ...
(Date:9/2/2014)... YORK , Sept. 2, 2014 ... is available in its catalogue: Acute ... http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html ... 2014 Summary GlobalData,s clinical trial ... H2, 2014" provides data on the Acute Heart ...
Breaking Medicine Technology:Depomed Announces Offering of $230 Million Convertible Senior Notes Due 2021 2Depomed Announces Offering of $230 Million Convertible Senior Notes Due 2021 3Market of Vital Signs Monitoring Devices Forecast to 2018 2Market of Vital Signs Monitoring Devices Forecast to 2018 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8
... 2007 - Lux Biosciences,Inc., a privately held biotechnology ... today that the company's,next-generation calcineurin inhibitor, LX211, is ... Research in Vision and,Ophthalmology (ARVO) annual meeting, being ... an oral presentation being given on May 5 ...
... at 59th American Academy of Neurology Annual Meeting, ... /PRNewswire/ --,PTC Therapeutics, Inc. (PTC), a biopharmaceutical company ... targeting,post-transcriptional control processes, today announced positive,interim data from ... patients,with Duchenne muscular dystrophy (DMD) due to a ...
Cached Medicine Technology:Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 2Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 3Lux Biosciences' Investigational Therapy for Uveitis, LX211, is,Subject of Two Presentations at Key Ophthalmology Meeting, ARVO,2007 4PTC Therapeutics Announces Additional Positive Interim Phase 2,Results of PTC124 in Duchenne Muscular Dystrophy 2PTC Therapeutics Announces Additional Positive Interim Phase 2,Results of PTC124 in Duchenne Muscular Dystrophy 3PTC Therapeutics Announces Additional Positive Interim Phase 2,Results of PTC124 in Duchenne Muscular Dystrophy 4PTC Therapeutics Announces Additional Positive Interim Phase 2,Results of PTC124 in Duchenne Muscular Dystrophy 5
(Date:9/3/2014)... September 03, 2014 An inspiring story ... be documented in the season finale of “Extreme Weight ... and his teenage daughter from Highlands Ranch, Colo. who ... she weighs 265 pounds. Their challenge is to team ... Featuring a unique, non-competitive approach to weight loss transformations, ...
(Date:9/3/2014)... Gorda, FL (PRWEB) September 03, 2014 ... healthcare delivery, increases patient safety, decreases medical errors, ... providers. , To mark the important role ... in America, IHS and others across the U.S. ... Technology (NHIT) Week , September 16-20, 2014. With ...
(Date:9/3/2014)... 2014 Independent review is a ... evidence-based health care along the continuum. Health plans, ... expertise of accredited independent review organizations (IROs) at ... , As a core function, IROs provide objective, ... of medical necessity. Yet backed by expertise, they ...
(Date:9/2/2014)... IA (PRWEB) September 03, 2014 IMCA ... will kick off on September 1, 2014 at the ... 6, the pre-race ceremony will include a check presentation ... For The Warriors® is a national nonprofit organization that ... the fallen who have sustained physical and psychological wounds ...
(Date:9/2/2014)... concentrated pot might be risky business for women, ... The study is the first to demonstrate sex ... , Psychology professor Rebecca Craft showed that, ... at least 30 percent more sensitive than males ... ingredient in cannabis. Females also develop tolerance to ...
Breaking Medicine News(10 mins):Health News:“Extreme Weight Loss”: Jeff and Juliana’s Journey begin at the University of Colorado Anschutz Health and Wellness Center 2Health News:Innovative Healthcare Solutions (IHS) Celebrates National Health IT Week September, 15-19, 2014 2Health News:Independent Review Expands Its Scope: Case Studies in Context 2Health News:Independent Review Expands Its Scope: Case Studies in Context 3Health News:IMCA to Present Donation to Hope For The Warriors 2Health News:Estrogen increases cannabis sensitivity 2Health News:Estrogen increases cannabis sensitivity 3
... is a statement by ADA President John S. ... (D-Mich.) and Candice Miller (R-Mich.) for introducing the ... that would bolster America,s capacity to respond to ... of the extensive education, training and professionalism of ...
... can divide into two, first it must duplicate its genetic ... of chromosomes then have to be separated from one another ... both daughter cells are genetically identical to the original, or ... called the centrosome, and a copy of the centrosome, position ...
... ONTARIO, CANADA Canada may not be able to ... brain drain of the mid-90s as a result of ... CMAJ published online today http://www.cmaj.ca/cgi/rapidpdf/cmaj.090209 . Health ... the public and government understand the impact of the ...
... (NYSE: RMD ) today announced record revenue and ... the December 2008 quarter was $223.0 million, a 10% increase ... quarter ended December 31, 2007. For the quarter ended ... net income was $33.9 million, an increase of 18% and ...
... study says , , THURSDAY, Feb. 5 (HealthDay News) -- Nearly ... that could lead to paralysis or death, but greater use ... a new study finds. , "Wearing a seat belt is ... against potentially devastating injury," said lead researcher Dr. Marjorie C. ...
... Feb. 5 A coalition of concerned consumer advocate ... Medical Consumers, called on the New York State Legislature ... pharmaceutical company gifts to doctors. This ban would exclude ... focus on gifts valued at over fifty dollars. Pharmaceutical ...
Cached Medicine News:Health News:Statement by ADA President John S. Findley on the Dental Emergency Responder Act Introduced Today by Reps. Stupak and Miller 2Health News:CSHL scientists discover link between control of chromosome duplication and segregation 2Health News:CSHL scientists discover link between control of chromosome duplication and segregation 3Health News:ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2008 2Health News:ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2008 3Health News:ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2008 4Health News:ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2008 5Health News:ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2008 6Health News:ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2008 7Health News:Spine Injuries a Common Result of Car Crashes 2Health News:Consumer Advocates Call on Legislature to Support Governor's Ban on Pharmaceutical Gifts to Doctors 2Health News:Consumer Advocates Call on Legislature to Support Governor's Ban on Pharmaceutical Gifts to Doctors 3
... Insulin-like growth factor II (IGF-II) is a ... the liver and is postulated to have mitogenic ... actions of IGF-II are mediated by binding to ... to the Type II IGF receptor, a monomeric ...
... (PAPP-A) is a large placenta-derived glycoprotein ... concentrations by placental trophoblast cells, and ... in increasing concentrations throughout gestation until ... to pregnancy since measurable levels have ...
... proteohormone with a molecular weight of 16 kDa. ... and produced by adipocytes [1,2]. Leptin is thought ... body weight [1-3]. In the human, leptin levels ... women [4]. A relationship between serum leptin levels ...
... known as Anti-Mullerian Inhibiting Substance (AMH), is ... kDa monomers linked by disulfide bridges (1). ... (TGF-?) superfamily which includes TGF-? and the ... members of this superfamily are dimeric glycoproteins, ...
Medicine Products: